Skip to main content
. 2019 Jul 12;317(3):H617–H626. doi: 10.1152/ajpheart.00177.2019

Fig. 2.

Fig. 2.

Morphological evaluation of chemogenetic heart failure after treatment with sacubitril/valsartan or valsartan. A: representative photographs of hearts from control and d-amino acid oxidase (DAAO)-expressing rats following treatments with water, sacubitril/valsartan (Sac/val), or valsartan alone (Val). B: measurements of heart weight to tibia length in control (n = 4) or DAAO-expressing rats (n = 6) treated with water and DAAO-expressing rats treated with sacubitril/valsartan (n = 6) or valsartan (n = 5). ***P < 0.001, ****P < 0.0001 obtained by one-way ANOVA with Šídák’s multiple-comparison test. Data are represented as means ± SE.